2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Biological Processes, Immune Mechanism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

5986 Long-term outcomes and prognostic determinants after reduced-toxicity haploidentical transplantation in older patients with myelodysplastic neoplasms

Wen-Jing Yu, MD, Yuqian Sun, MD2, Xiaohui Zhang, MD3, Lanping Xu, MD4, Xiao-Dong Mo, MD5, Meng Lv6, Xiaojun Huang, MD, PhD7, Yu Wang8
1 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
3 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
5 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
6 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
7 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China, State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China
8 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative therapy for myelodysplastic neoplasms (MDS), but regimen-related toxicity and transplant-related mortality (TRM) limit its use in older adults. We evaluated long-term outcomes and disease-, patient-, and graft-related prognostic determinants after T-cell-replete haploidentical HSCT using a reduced-toxicity conditioning (RTC) platform in patients aged ≥60 years with MDS.

Methods: This updated cohort analysis of a prospectively registered, single-arm phase 2 RTC platform (NCT03412409) included 122 consecutive patients aged ≥60 years who underwent haploidentical HSCT at a single center from 2016 through 2025. Prospective enrollment began in 2018; patients transplanted in 2016-2017 under the same protocol were included with extended follow-up. Conditioning comprised cytarabine (4 g/m² total), busulfan (9.6 mg/kg), fludarabine (150 mg/m²), cyclophosphamide (2 g/m²), semustine (250 mg/m²), and rabbit antithymocyte globulin (10 mg/kg); GVHD prophylaxis comprised cyclosporine, mycophenolate mofetil, and short-course methotrexate. Endpoints included engraftment, infection, GVHD, relapse, TRM, disease-free survival (DFS), and overall survival (OS). Cumulative incidence functions accounted for competing risks; DFS and OS were estimated by Kaplan-Meier analysis. Fine-Gray and Cox regression models identified factors associated with relapse/TRM and DFS/OS, respectively.

Results: Median age was 63 years (range, 60-77); 82 patients (67.2%) were male. At transplantation, 89 (73.0%) had Revised International Prognostic Scoring System (IPSS-R) high/very high disease, 41 (33.6%) had Molecular International Prognostic Scoring System (IPSS-M) high/very high disease, and 18 (14.8%) had a Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) ≥3. Median follow-up among survivors was 27.4 months (range, 2.3-120.1). Neutrophil and platelet engraftment occurred in 98.4% and 92.6%, with median recovery at 13 and 16 days, respectively. The 1-year cumulative incidences of cytomegalovirus and Epstein-Barr virus infection were 36.5% and 22.0%. By day 100, grade II-IV and III-IV acute GVHD incidences were 24.0% and 10.2%; moderate-to-severe chronic GVHD was 18.2% at 1 year and 19.2% at 3 years. During follow-up, 10 patients relapsed, 27 died without relapse, 37 had a DFS event, and 34 died. Relapse incidence was 6.4%, 9.1%, and 12.6% at 1, 3, and 5 years. TRM was 10.8% at day 100 and 23.1%, 24.2%, and 24.2% at 1, 3, and 5 years. DFS was 70.5%, 66.7%, and 63.2% at 1, 3, and 5 years; corresponding OS was 71.9%, 68.3%, and 68.3%. At 5 years, 95% confidence intervals (CIs) were 4.8%-21.7% for relapse, 16.5%-32.6% for TRM, 51.3%-73.0% for DFS, and 58.3%-76.3% for OS. In multivariable analyses, IPSS-M high/very high risk independently predicted relapse (subdistribution hazard ratio [SHR], 4.29; 95% CI, 1.11-16.7; P=.035), TRM (SHR, 3.40; 95% CI, 1.51-7.67; P=.003), inferior DFS (hazard ratio [HR], 3.23; 95% CI, 1.66-6.27; P<.001), and inferior OS (HR, 3.05; 95% CI, 1.53-6.09; P=.002). Age >65 years (SHR, 2.24; 95% CI, 1.03-4.86; P=.042) and HCT-CI ≥3 (SHR, 2.45; 95% CI, 1.00-5.96; P=.049) independently increased TRM. World Health Organization category was independently associated with DFS and OS (global P=.034 and P=.020). Infusion of >3.98×10^6 CD34-positive cells/kg was associated with higher overall TRM (SHR, 3.15; 95% CI, 1.36-7.31; P=.007) and 100-day TRM (SHR, 4.17; 95% CI, 1.15-15.15; P=.030), whereas >7.085×10^8 mononuclear cells/kg was associated with lower 100-day TRM (SHR, 0.30; 95% CI, 0.09-0.98; P=.046).

Conclusions: RTC-based haploidentical HSCT provided durable disease control and clinically meaningful 5-year survival in selected patients aged ≥60 years with MDS. IPSS-M high/very high risk identified patients with both increased relapse and TRM and markedly inferior survival, while age >65 years and HCT-CI ≥3 further defined TRM vulnerability. The graft-dose associations were exploratory and require external validation. These findings support transplantation based on integrated biological risk, comorbidity, and fitness rather than chronological age alone and provide a rationale for risk-adapted conditioning, graft optimization, and intensified peri-transplant management in high-risk subgroups.

Wen-Jing Yu, MD: No relevant conflicts of interest to declare.